|Day Low/High||0.18 / 0.20|
|52 Wk Low/High||0.15 / 1.30|
CE Marking Allows CGI's DNA-FISH Probe, FHACT(R), to be Widely Marketed in European Economic Area, Which Covers 31 Countries
Conference Call Today at 8:30 a.m. Eastern / 5:30 a.m. Pacific
CGI's Proprietary Genomic Panel for Diagnosis and Risk Stratification of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) is Now Licensed to Report Out Risk Stratification of Patients Into Three Distinct Groups
Upgrades: AMCX, AWRE, IXYS, LMNR, MMYT, MPAA, NATI, PLPM, SGOC, TCPC Downgrades: CGIX, GPRC, NRT, PRSS Initiations: AMBI, TEP Read on to get TheStreet Quant Ratings' detailed report:
Upgrades: ANCB, FRBK, KOS, VOC Downgrades: BIRT, FIG, FRP, GLDC, GLPW, HNH, INS, JBT, KRNY, MCC, PKOH, PKT, QLYS, SCSC, SGA Initiations: CGIX, IBTX, OAKS Read on to get TheStreet Quant Ratings' detailed report:
IPO Desktop President Francis Gaskins believes these IPOs are only for risk takers. Cancer Genetics has lost money and Orchid Island suffers from legal problems.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.